Covid 19 the European Union is studying a new German

Covid 19: the European Union is studying a new German vaccine based on D containing nanoparticles

The nanoparticles contained in the Skycovion contain elements of the spike protein, which occurs naturally on the surface of the Covid virus Sars-Cov-2 and allows it to penetrate the body’s cells.

Article written byplaceholder 36b69ec8

Posted on 08/18/2022 21:44 Updated on 08/18/2022 21:45

Reading time: 1 min

One of the new tracks in the fight against the pandemic. The European Medicines Agency (EMA) issued a statement on Thursday 18th

According to the agency, the Skycovion vaccine contains nanoparticles that contain elements of the spike protein. This protein, which is on the surface of the Covid-Sars-Cov-2 virus and allows it to enter human cells, is also the one that the body creates during vaccination with a messenger RNA vaccine, according to the ministry reminded The Health.

The vaccine, developed by SK Chemicals, also contains an adjuvant to boost the body’s immune response to the vaccine, the agency said. EMA adds that SK Chemicals “has provided data on the ability of this new vaccine to elicit the production of antibodies against the parent strain of SARS-CoV-2” and “the safety and quality of the vaccine”.

If approved, Skycovion will be the seventh vaccine approved in the European Union. Others are already under review by the EMA in anticipation of a possible resurgence of the pandemic in the autumn, such as a version of the Moderna vaccine adapted to the Omicron variant. Currently, the European Union has approved the use of vaccines developed by AstraZeneca, Janssen, BioNTech-Pfizer, Moderna, Novavax and Valneva, the latter of which have since ceased production.